The pharmaceutical industry spent over $US4 billion advertising prescription drugs directly to consumers in the US in 2004. The use of direct-to-consumer advertising (DTCA) has been a source of great controversy. Supporters of DTCA argue that it provides an important source of health information for consumers, increases the treatment of under diagnosed conditions and improves medication adherence. Critics argue that it misleads consumers, leads to overuse of medications, drives up prescription drug prices and costs, and harms the doctorpatient relationship.
It has been 9 years since the US Food and Drug Administration (FDA) altered its policy to make broadcast advertisements for prescription drugs more feasible. [1] Spending on direct-toconsumer advertising (DTCA) for prescription drugs now exceeds $US4 billion per year in the US -one of only two industrialised countries to allow product-specific mass media advertising for prescription drugs. [2, 3] DTCA is used to promote a range of pharmaceutical products from those used to treat depression, sexually transmitted diseases and hyperlipidaemia to so-called 'lifestyle drugs' such as medications for erectile dysfunction. Pharmaceutical products are now among the most heavily advertised products in the US. In fact, Pfizer spent more advertising its products to consumers than did the Ford Motor Company in 2003. [4] The use of DTCA in the US has been a focus of vigorous debate since the first DTC campaigns for prescription drugs began in the early 1980s. Supporters of DTCA argue that it provides an important source of health information for consumers, increases treatment of under-recognised conditions and leads to better medication adherence. [5] [6] [7] [8] As evidence of the beneficial effects of DTCA, proponents point to a number of consumer surveys that suggest that drug advertising encourages consumers to seek treatment for a range of serious chronic conditions, some of which had previously gone undiagnosed. [9] [10] [11] On the other hand, critics of DTCA argue that it misleads consumers, leads to overuse of medications, drives up prescription drug prices and costs, and harms the doctor-patient relationship. [12] [13] [14] [15] [16] [17] As evidence of the deleterious effects of drug advertising, critics often point to the low informational content of drug adverts, particularly the fact that pharmaceutical product benefits are featured much more prominently in drug adverts than are product risks. [18] [19] [20] [21] [22] [23] [24] Which view of DTCA prevails depends in part on the particular condition, pharmacological class, pharmaceutical product and, perhaps, even the advertising campaign of interest. It is useful to view the effects of DTCA within the broader context of problems with the quality of prescription drug use. Three major categories of suboptimal prescribing exist: 1. overuse 2. inappropriate use 3. underuse. [25] Overuse of a medication has been defined as the use of a drug for which there is no indication. [26] Medication use is considered inappropriate when a drug has more potential risk than benefit or prescribing of the medication does not agree with accepted medical standards. [27] [28] [29] Inappropriate medication use includes prescriptions written for:
• an inappropriate duration;
• too high or too low a dose;
• a drug that is contraindicated;
• drugs that could cause drug-drug interactions;
• a drug for which more effective and less costly alternatives are available. [30] Underuse is the omission of drug therapy that is indicated for the treatment or prevention of a disease or condition. [31] Patient demand for prescription drugs, whether or not it is triggered by pharmaceutical promotion, may exacerbate problems with overuse or inappropriate use, or mitigate problems with underuse, or affect all three at once. Evidence on the effects of DTCA should be weighed in terms of its impact on these three domains of problems with medication use.
While the literature on DTCA offers little direct evidence on its impact on overuse, inappropriate use or underuse, a number of marketing studies on the demand effects of DTCA provide indirect evidence on the effects of DTCA on public health. Moreover, a handful of recent studies shed light on the impact of DTCA on the appropriateness of medication use. [32] [33] [34] [35] This article briefly discusses current trends in the pharmaceutical industry's use of DTCA in the US. It then reviews the empirical evidence on the impact of DTCA on pharmaceutical demand and the few studies that directly assess the impact of DTCA on underuse, inappropriate use and overuse of prescription drugs. The implications of the empirical findings for the current policy debate over DTCA and directions for future research are then discussed. The first search used the terms direct-to-consumer, prescription drugs and spending. Descriptive analyses of DTCA spending and studies that examined predictors of DTCA spending were included. A second search on the demand effects of DTCA was conducted using a combination of the following terms: direct-toconsumer, prescription drugs, market share, market size or demand. Only empirical papers with a quasi-experimental or experimental study design yielded from this second search were included.
Methods

Trends in Spending on Direct-to-Consumer Advertising (DTCA)
Pharmaceutical industry spending on DTCA increased dramatically in the late 1990s from $US791 million in 1996 (the year before FDA policy change) to $US4 billion in 2004 (see figure 1) ; the majority of DTCA spending in 2004 was on television adver- [3] tisements. While this is a large amount, studies show that DTCA makes up only a relatively small share of the total industry spending on promotion -the majority of the promotions budget is aimed at physicians. [36] [37] [38] For instance, Rosenthal and colleagues [36] reported that DTCA accounted for less than 16% of total promotional spending in 2000. Another study found that DTCA made up only 11% of total promotional spending for the 250 most heavily promoted drugs in 1998. [37] The two biggest categories of promotional spending were free samples of medicines and detailing 1 to physicians.
These studies are likely to understate the magnitude of pharmaceutical companies' investments in mass media advertising for several reasons. First, in order to use a common metric, spending on free samples is often provided in terms of its retail value which overstates the cost to the manufacturer. If samples were valued at their true opportunity cost (manufacturing cost plus the costs of delivering samples to physicians, and costs associated with some foregone sales), DTCA along with other forms of promotion would make up a larger share of dollars spent on promotion. Unfortunately, it is very difficult to estimate the true cost of free samples to pharmaceutical manufacturers. Second, and more importantly, DTCA spending is highly concentrated in a few brands so industry totals mask substantial variation in spending on this form of promotion. [25, 39, 40] Median spending on DTCA is zero. Among therapeutic categories with at least some DTCA, pharmaceutical manufacturers devoted an average of 20% of their promotional budget to DTCA with a great deal of variation around the mean. [37] Ma and colleagues [37] found that more was spent on DTCA than on detailing for drugs in four therapeutic classes -antihistamines, urinary tract medications, smoking cessation products and antivirals.
Which Drugs are Advertised to Consumers?
Given that relatively few products are promoted directly to consumers, assessing which products use DTCA may provide some insights into the industry's view of the effects of this form of promotion. In the most comprehensive study of the product and market-level determinants of spending on DTCA, Iizuka [40] examined a total of 606 drug-year observations for 169 unique brandname drugs over the period 1996-1999. He found that DTCA was more likely to be used for newer drugs, drugs that were first in their class and drugs in classes with fewer brandnames than generics. He also found that high-quality drugs were more likely to advertise to consumers although his measurement of quality (FDA rating) is subject to considerable error. Iizuka [40] examined the impact of market size on DTCA spending and found that pharmaceutical firms spend more on DTCA if the untreated, as opposed to the treated, population is large. This suggests that pharmaceutical firms view the effects of DTCA as market-expanding.
Depending on one's view, Iizuka's findings could either be good or bad news for DTCA. Opponents of DTCA point to the fact that advertising expenditures are lower for drugs in highly competitive classes and higher for new, more expensive drugs. This finding may lend support to the argument that DTCA leads to inefficient spending on prescription drugs. Supporters of DTCA, on the other hand, point to the fact that innovative, highquality medications used to treat under-diagnosed conditions are more likely to use DTCA. There is most likely some element of truth to the arguments on both sides of the debate and it is important to assess the net effects of DTCA.
Effects of DTCA on Pharmaceutical Demand: Alleviating Underuse?
A number of studies have been conducted on the demand effects of DTCA. [41] [42] [43] [44] [45] [46] [47] [48] These studies have been primarily published in economics and marketing journals and are not widely cited in peer-reviewed papers in the medical and public health fields. Yet, they have important implications for measuring the public health effects of DTCA. The studies relate to the impact of DTCA on the problem of the underuse of medications. Specifically, the studies (reviewed below) look at the impact of DTCA on market size and market share. If the only outcome of DTCA is to increase the market share for the advertised drug, then DTCA is not likely to affect public health in any significant way unless there are large differences between the advertised and unadvertised drugs in terms of safety or effectiveness. If, on the other hand, DTCA expands the size of the market it is important to examine the health implications of the expanded use.
Marketing studies suggest that DTCA expands total class sales but has little influence on individual product market share. This finding has held across studies in multiple therapeutic classes using a range of statistical methods and data sources. [41] [42] [43] [44] [45] [46] [47] [48] [49] The implications of this finding are that DTCA is not focused entirely on 'business stealing' or shifting consumer preferences from a nonadvertised, inexpensive drug to an advertised, expensive drug -though that is the effect of other forms of pharmaceutical promotion (detailing, as discussed later in this section.
Rosenthal and colleagues [41] examined the impact of DTCA spending on aggregate sales of prescription drugs in five therapeutic classes with high DTCA expenditures (antidepressants, proton pump inhibitors, antihistamines, cholesterol-lowering medications and nasal sprays) between 1997 and 1999. The study found that while DTCA had no statistically significant effect on the market share of individual products, it was effective at generating increased sales to the therapeutic class as a whole. The estimated advertising elasticity was 0.10, in other words a 10% increase in total class DTCA spending resulted in a 1% increase in total sales to the therapeutic class. Applying this elasticity to sales data for the 25 largest therapeutic classes, the authors find that between 13% and 22% of the increase in total prescription drug spending growth between 1999 and 2000 was attributable to DTCA.
A study of aggregate sales data for nonsedating antihistamines found that DTCA spending had a positive effect on total class sales while detailing had no effect on class sales. [42] On the other hand, detailing spending had a significant, large, positive effect on product market share while DTCA had a much smaller effect on share within the class. The share elasticity estimates were 0.01 and 0.05 for DTCA and detailing, respectively.
Two studies of the impact of DTCA on medication choice support the claim that DTCA has little to no effect on market share. Using aggregate-level data on DTCA spending and detailing, and individual-level claims data from Blue Cross Blue Shield, Wosinska [43] found that DTCA for cholesterol-lowering drugs had a small positive impact on drug choice, but only for drugs with a preferred status on the health plan's formulary (i.e. lower co-pays than other brands). The prescription co-pay × DTCA interaction effect was confirmed by another study of the proton pump inhibitor class. [44] Moreoever, the study found that detailing had an effect on drug choice that was five times that of DTCA.
In a study of the antidepressant class, Donohue and Berndt [45] examined the association between product-level spending on DTCA and detailing, and drug choice for individuals beginning antidepressant treatment using Thomson's MarketScan™ data. The study found that for antidepressant users as a whole, DTCA spending had no effect on a medication's choice probability. For the subset of patients with an anxiety disorder, DTCA spending increased a drug's choice probability slightly although its effect on choice was much smaller than that of detailing. A one standard deviation increase in DTCA increased a drug's choice probability by 0.5%, while a one standard deviation increase in detailing increased the probability by 15%.
A study of aggregate sales and promotional spending in the prescription antiulcer and heartburn (histamine H 2 receptor antagonists) market found that quantities of prescription H 2 antagonists demanded were not significantly related to DTCA spending but were positively related to physician marketing (e.g. detailing and free samples). This particular study, which examined data from 1988 to 1999, did not address the market size or class effect issue. [46] Only one economic study that examined the impact of DTCA on the total size of the market found no effect. Using aggregate data on sales and promotion in the statin (HMG-CoA reductase inhibitor) class, Calfee et al. [47] found that advertising had no statistically significant effect on either the total number of prescriptions sold in the class or on market share. The use of aggregate prescription sales data did not allow the authors to identify new versus continuing users.
Using another measure of market-expanding effects, Iizuka and Jin [48] examined the association between class-level DTCA spending and physician visits that resulted in a prescription drug being prescribed, an over-the-counter medication being recommended or nonpharmacological treatment recommended. The study assessed the correlation between physician visits using data from the National Ambulatory Medical Care Survey between 1995 and 2000 and DTCA spending between 1994 and 2000. The study found that DTCA spending was associated with a significant increase in the number of physician visits in which a drug was prescribed or an over-the-counter medication recommended.
The bottom line appears to be that DTCA primarily boosts sales by expanding total use of the class and that one drug's advertising increases its competitors' sales along with its own. So why do pharmaceutical manufacturers continue to invest in DTCA if it has no effect on market share? Most of these studies assessed the effects of advertising campaigns early in the life of DTCA (shortly after the FDA policy change made broadcast advertising feasible). There was likely to be a great deal of experimentation and the quality of the marketing efforts may have been weaker at the beginning. It is possible that contemporary DTCA campaigns have demonstrated an impact on market share and that this outcome drives continued investment in DTCA. Assuming, however, that these findings are accurate -that DTCA spending boosts total class sales but does not increase a drug's share of the market -firms may still have an incentive to invest in DTCA if it complements other forms of promotion. It can be argued that DTCA and detailing should be viewed as complementary strategies. Firms may invest in DTCA not because of its independent effect on market share but because it makes detailing efforts more successful by expanding the size the market. Indeed, the theoretical economics literature suggests that DTCA and detailing should be viewed as complementary marketing strategies. [49] DTCA generates physician visits and patient medication requests but once the patient requests a prescription, physician preferences determine which brand is selected. Detailing, and other forms of pharmaceutical promotion aimed at physicians, are focused on influencing physician preferences for one brandname over another.
Impact on Problems with Inappropriate Use or Overuse?
If DTCA boosts sales by expanding medication use, the key question that remains is whether the expanded use is predominantly appropriate (i.e. it addresses problems with underuse of medications) or predominantly inappropriate (e.g. improper duration or dose, contraindication, etc.). Unfortunately, only a few studies bear directly on these issues. Donohue and colleagues [32] examined the treatment patterns of 30 521 patients with depression who were initiating a new episode of treatment between 1997 and 2000 using Thompson's MarketScan™ database. The analysis assessed the correlation between temporal variation in class-level DTCA and free samples spending and the likelihood that an individual diagnosed with depression receives medication treatment. They find that individuals diagnosed with depression following periods of high antidepressant DTCA spending were 6% more likely to receive medication treatment in the first 6 months of an episode of depression than those diagnosed following periods of low DTCA spending. [32] The study also examined whether antidepressant DTCA and detailing spending were associated with greater adherence to treatment guidelines for depression. Individuals diagnosed following periods of high antidepressant DTCA spending were 5% more likely to fill at least 4 prescriptions for antidepressants in 6 months than individuals diagnosed following periods of low DTCA spending. Pharmaceutical promotion directed at physicians was not found to be associated with either medication treatment initiation or adherence. This study offers preliminary evidence that DTCA addresses the problems of underuse of antidepressant medication. But administrative data do not provide information on the severity of illness and this analysis cannot distinguish between those who met full diagnostic criteria for depression versus those who did not.
Wosinska [33] examined the impact of DTCA on adherence to medication therapy for cholesterol-lowering medications (statins) using data on DTCA spending and insurance claims data from Blue Cross Blue Shield of California from 1996 to 1999. She found that a 10% increase in class-level DTCA spending for statins only reduced the number of missed days between prescription refills by 0.5% on average. The analysis did not directly examine the relationship between DTCA and therapy persistence.
Spence and colleagues [34] examined the association between DTCA exposure and the appropriateness of cyclo-oxygenase-2 (COX-2) inhibitor use. The study linked administrative claims data with survey data that measured exposure and behaviour related to prescription drug advertising. The study found that 78% of patients who were exposed to DTCA for a COX-2 inhibitor and asked for a prescription received it, compared with 43% of patients who either did not see an advert or saw an advert but did not talk to their physician. Only 21% of patients who saw or heard a COX-2 advert and asked for a prescription were appropriately treated versus 55% of patients who did not request a prescription due to a drug advert. Treatment with a COX-2 was considered appropriate if the patient was at risk of gastrointestinal bleeding using three different measures of risk. This study, while suggestive of inappropriate use, used nonequivalent control groups and so it is difficult to draw inferences about the effects of DTCA on appropriateness of prescribing.
The only experimental study to directly address whether DTCA leads to overuse, inappropriate use or ameliorates underuse was recently published in JAMA by Kravitz et al. [35] They conducted a randomised, controlled trial using standardised patients (SPs) -trained actors presenting to physicians with symptoms of depression -to address four research questions: 1. What are the effects of patients' requests for antidepressants on physician prescribing? 2. Does it make a difference whether patients' requests are brand-specific or general? 3. Do the effects of patients' requests vary depending on the clinical indication for antidepressant therapy? 4. What are the effects of brand-specific and general requests on mental health referral and primary-care follow-up?
The SPs presented to physicians with either symptoms of major depression, for which medication treatment is clinically indicated, or symptoms of adjustment disorder, for which there is no expert consensus about need for treatment. The two conditions were then crossed with three request types (brand-specific requests for paroxetine, general medication requests or no medication requests) creating six SP roles.
Physicians prescribed antidepressant medications in 54% of the visits in which SPs portrayed major depression and in 34% of the visits for adjustment disorder. The probability of receiving medication among SPs portraying major depression was highest among those making general requests (76%) compared with those making brand-specific (53%) or no request for medication (31%). In comparison, SPs portraying adjustment disorder were most likely to receive medication treatment if they made brandspecific requests (55%) compared with general requests (39%) or no requests (10%). Requests for specific medication (paroxetine) were more likely to be honoured in the adjustment disorder group than the major depression group. Only 19% of SPs presenting with symptoms of major depression but making no medication requests were referred to mental health specialty care.
These findings suggest that DTCA may expand treatment for conditions like depression which are substantially underrecognised by providers and often go untreated. But the study also suggests that DTCA may lead to some overuse. The fact that among SPs with major depression those who requested medication were more than twice as likely to receive treatment as those who merely presented with symptoms provides strong evidence for the assertion that patient requests influence prescribing behaviour. Future studies should build on this experimental work to examine the impact of DTCA on appropriateness of prescribing for other conditions.
Discussion
By 2004, DTCA seemed to have weathered the raft of criticism it encountered in the late 1990s. The FDA's own research, which relied on surveys of consumers and physicians, led agency officials to claim a few years ago that "DTC promotion offers public health benefits that may outweigh potential costs." [50] The September 2004 withdrawal of rofecoxib (a COX-2 inhibitor sold under the proprietary name Vioxx ® ) due to evidence of increased cardiovascular risk changed the political debate over DTCA. Rofecoxib was heavily advertised to consumers, ranking highest in DTCA spending in 2000 [36] and COX-2 inhibitors became a widely used class of medications. DTCA no doubt contributed to this widespread use. Since rofecoxib's withdrawal, calls for stricter limits and even a ban on DTCA for some drugs have been renewed. The focus of criticism of DTCA has shifted somewhat from its effects on drug costs to its effect on patient safety, thus elevating the level of political attention the issue receives. In fact, the US Senate majority leader William Frist, who is a surgeon and is considered a congressional leader on healthcare issues, recently called for a 2-year voluntary moratorium on the use of DTCA for newly approved drugs. [51] In June 2005, Bristol Myers Squibb announced a 1-year moratorium on DTCA for new product launches. Pfizer announced a voluntary moratorium on DTCA for celecoxib, its COX-2 inhibitor, in 2004.
Efforts to regulate DTCA more tightly should be based on what is known about the impact of DTCA on public health. Preliminary evidence from quasi-experimental and experimental studies supports the argument that DTCA expands the use of prescription drugs, and that it may mitigate problems with underuse while at the same time leading to some overuse. It is important to look carefully at the costs and benefits associated with underuse, inappropriate use and overuse associated with DTCA. Recent studies of the quality of care suggest that, at least in the US healthcare system, problems with the underuse of pharmaceuticals are more widespread than problems with overuse. [52] Costs from a societal perspective may include prescription drug costs, healthcare costs associated with physician visits, healthcare costs associated with adverse drug events, as well as physician and patient time costs. On the benefits, studies should assess the impact of DTCA-related use on mortality and morbidity, productivity and functioning. Whether the costs of DTCA exceed the benefits may depend on the condition studied. As Kravitz and colleagues [35] point out, "[t]he benefits of advertising will tend to dominate when the target condition is serious and the treatment is very safe, effective and inexpensive. Harms are most likely to emerge when the target condition is trivial and the treatment is relatively perilous, ineffective or costly."
There is a need for formal cost-benefit analyses to be conducted on the impact of DTCA in a variety of medication classes. Before such analyses can be conducted, however, we need to fill some gaps in the literature. We know, from the studies reviewed in this paper, about the marketing elasticities of DTCA (i.e. the increase in sales associated with spending on DTCA). We also know which drugs are advertised and the conditions they are intended to treat. In some cases, we can measure the impact of pharmacological treatment on morbidity and mortality associated with those conditions. Because of an experimental study we know something about the likelihood that physicians honour their patients' medication requests with a prescription, although future studies are needed to validate this finding. Findings from two studies are suggestive of a small positive impact of DTCA on medication adherence although more work should be conducted in this area. However, significant gaps persist in our understanding of the subpopulation that responds to DTCA. What proportion of consumers requesting medication as a result of DTCA actually stand to benefit from pharmacological treatment compared with the number for whom pharmacotherapy is on the mar-gin of clinical effectiveness? This important issue deserves further study.
